234 related articles for article (PubMed ID: 35875870)
41. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
Ceppi F; Rivers J; Annesley C; Pinto N; Park JR; Lindgren C; Mgebroff S; Linn N; Delaney M; Gardner RA
Transfusion; 2018 Jun; 58(6):1414-1420. PubMed ID: 29536556
[TBL] [Abstract][Full Text] [Related]
42. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
43. Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas.
Deshpande A; Rule W; Rosenthal A
Curr Treat Options Oncol; 2022 Jan; 23(1):89-98. PubMed ID: 35167008
[TBL] [Abstract][Full Text] [Related]
44. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
45. Group O plasma as a media supplement for CAR-T cells and other adoptive T-cell therapies.
Nelson RC; Fellowes V; Jin P; Liu H; Highfill SL; Ren J; Szymanski J; Flegel WA; Stroncek DF
Transfusion; 2020 May; 60(5):1004-1014. PubMed ID: 32167176
[TBL] [Abstract][Full Text] [Related]
46. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
47. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
48. Practical aspects of CAR-T cell therapy.
Jana M; Tomáš J; Michal K; Kateřina B; Juraj U; Ivo D; Zdeněk K; Roman H
Klin Onkol; 2022; 35(1):44-54. PubMed ID: 35236081
[TBL] [Abstract][Full Text] [Related]
49. Large-scale manufacturing and characterization of CMV-CD19CAR T cells.
Wang X; Urak R; Walter M; Guan M; Han T; Vyas V; Chien SH; Gittins B; Clark MC; Mokhtari S; Cardoso A; Diamond DJ; Zaia J; Forman SJ; Nakamura R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35027426
[TBL] [Abstract][Full Text] [Related]
50. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
Chandran SS; Klebanoff CA
Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
[TBL] [Abstract][Full Text] [Related]
51. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
52. Resisting CAR T-cell Therapy: A Case Study.
Cancer Discov; 2018 Dec; 8(12):1499-1500. PubMed ID: 30366924
[TBL] [Abstract][Full Text] [Related]
53. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
Schmidts A; Marsh LC; Srivastava AA; Bouffard AA; Boroughs AC; Scarfò I; Larson RC; Bedoya F; Choi BD; Frigault MJ; Bailey SR; Leick MB; Vatsa S; Kann MC; Prew MS; Kleinstiver BP; Joung JK; Maus MV
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900862
[TBL] [Abstract][Full Text] [Related]
54. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
55. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
56. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Brookens SK; Posey AD
Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
[TBL] [Abstract][Full Text] [Related]
57. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
58. Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors.
Mo F; Mamonkin M
Methods Mol Biol; 2020; 2086():119-130. PubMed ID: 31707671
[TBL] [Abstract][Full Text] [Related]
59. Quality Assessment of Pre-Clinical Studies of Chimeric Antigen Receptor T-Cell Therapy Products: A Point of Focus on Safety.
Maharshi V; Diksha D; Gupta P
Curr Drug Saf; 2022; 17(2):129-135. PubMed ID: 34323195
[TBL] [Abstract][Full Text] [Related]
60. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
Myburgh R; Kiefer JD; Russkamp NF; Magnani CF; Nuñez N; Simonis A; Pfister S; Wilk CM; McHugh D; Friemel J; Müller AM; Becher B; Münz C; van den Broek M; Neri D; Manz MG
Leukemia; 2020 Oct; 34(10):2688-2703. PubMed ID: 32358567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
